Age, Biography and Wiki
Jonathan Baell was born on 1965, is an Australian medicinal chemist. Discover Jonathan Baell's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 59 years old?
| Popular As |
N/A |
| Occupation |
N/A |
| Age |
59 years old |
| Zodiac Sign |
N/A |
| Born |
1965 |
| Birthday |
|
| Birthplace |
N/A |
| Nationality |
|
We recommend you to check the complete list of Famous People born on .
He is a member of famous with the age 59 years old group.
Jonathan Baell Height, Weight & Measurements
At 59 years old, Jonathan Baell height not available right now. We will update Jonathan Baell's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status |
| Height |
Not Available |
| Weight |
Not Available |
| Body Measurements |
Not Available |
| Eye Color |
Not Available |
| Hair Color |
Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family |
| Parents |
Not Available |
| Wife |
Not Available |
| Sibling |
Not Available |
| Children |
Not Available |
Jonathan Baell Net Worth
His net worth has been growing significantly in 2023-2024. So, how much is Jonathan Baell worth at the age of 59 years old? Jonathan Baell’s income source is mostly from being a successful . He is from . We have estimated Jonathan Baell's net worth, money, salary, income, and assets.
| Net Worth in 2024 |
$1 Million - $5 Million |
| Salary in 2024 |
Under Review |
| Net Worth in 2023 |
Pending |
| Salary in 2023 |
Under Review |
| House |
Not Available |
| Cars |
Not Available |
| Source of Income |
|
Jonathan Baell Social Network
| Instagram |
|
| Linkedin |
|
| Twitter |
|
| Facebook |
|
| Wikipedia |
|
| Imdb |
|
Timeline
Jonathan Baell (né Ball) is trained as an Australian medicinal chemist and is currently executive director, early leads chemistry at Lyterian Therapeutics in San Francisco.
Prior to this, he was a research professor in medicinal chemistry at the Monash Institute of Pharmaceutical Sciences (MIPS), the director of the Australian Translational Medicinal Chemistry Facility and a Chief Investigator at the ARC Centre for Fragment-Based Design.
Baell was born in Tanzania, East Africa in 1965.
He migrated with his family to Tasmania, Australia in 1977.
Baell completed a Bachelor of Science with Honours from the University of Tasmania in 1986.
He then moved to Melbourne to undertake a PhD project with Professor Peter Andrews and Professor Paul Alewood at the Monash University Faculty of Pharmacy and Pharmaceutical Sciences (previously known as the Victorian College of Pharmacy), graduating in 1992.
At the completion of his PhD, Baell commenced his postdoctoral research at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), quickly rising to the rank of senior research scientist at the age of 28.
In 2001, Baell moved to the Walter and Eliza Hall Institute (WEHI), where he served as the Head of Medicinal Chemistry for the subsequent decade.
During this time, Baell published a paper in the Journal of Medicinal Chemistry describing a naturally occurring chemical derived from Ammi visnaga, khellinone, as the basis of a potential new class of immunosuppressive drugs for the treatment of multiple sclerosis.
This area of research won him the Biota Award for Medicinal Chemistry from the Royal Australian Chemical Institute (RACI) in 2004.
2004 - Biota Award for Medicinal Chemistry, RACI
His 2010 publication identified the chemical structures of these compounds and constructed electronic filters that can be used in HTS campaigns to remove PAINS from screening hits.
After 10 years at WEHI, Baell moved his research lab to MIPS, where he was appointed as a research professor in 2012.
Baell coined the term PAINS (pan-assay interference compounds) to describe chemical compounds that are often picked up as false positive hits from HTS campaigns.
The implications of PAINS in the drug discovery pipeline resulted in the American Chemical Society to include the removal of PAINS from screening hits as a publication requirement for its journals in 2017.
He was President of the International Chemical Biology Society 2018-2021 and is currently chair of the board.
His research focuses on the early stages of drug discovery, including high-throughput screening (HTS) library design, hit-to-lead and lead optimization for the treatment of a variety of diseases, such as malaria and neglected diseases.
In 2018, Baell was awarded the Adrien Albert Award by RACI.
It is the most prestigious award for RACI Medicinal Chemistry & Chemical Biology Division, given for exceptional research in the field of medicinal chemistry, agricultural chemistry or chemical biology.
2018 - Adrien Albert Award, RACI
2019 - Faculty Research Award, Monash University Faculty of Pharmacy and Pharmaceutical Sciences
The impact of Baell's work on PAINS was recognized in 2020 when he was presented the Scientific Achievement Award in Drug Discovery and Development by the American Society for Pharmacology and Experimental Therapeutics.
2020 - Scientific Achievement Award in Drug Discovery and Development, ASPET
According to the Espacenet database, Baell has registered 49 patents as of July 2020.
